Prexige TARGET Study: Not Quite A Bull's-Eye For Novartis
This article was originally published in The Pink Sheet Daily
Executive Summary
The study found a lower risk of gastrointestinal side effects for Prexige compared to ibuprofen and naproxen, but the incidence of serious liver abnormalities was higher for the COX-2 than for the NSAIDs.
You may also be interested in...
Novartis Will Resubmit COX-2 Inhibitor In The U.S. In 2007
Prexige is approved in EU and Canada for osteoarthritis symptoms, company announces.
Novartis Will Resubmit COX-2 Inhibitor In The U.S. In 2007
Prexige is approved in EU and Canada for osteoarthritis symptoms, company announces.
Prexige 2007 Filing Target Assumes FDA Will Request Additional CV Data
Novartis assumes FDA will require two-year cardiovascular data for COX-2s following the withdrawal of Merck's Vioxx. Company expects to have "more detailed discussions" with the agency in early 2005 after FDA reviews 12-month data from the Prestige TARGET study.